These findings suggest that CHIP modulates ER stress and inflammatory responses by inhibiting TXNIP, and that CHIP protects against TM- or HF–HS diet-induced NAFLD and serves as a potential therapeutic means for treating liver diseases. The gene discussed is TXNIP; the disease is metabolic dysfunction-associated steatotic liver disease.